Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02207491 · ClinicalTrials.gov registry record · Phase 3
Double-masked Study of AR-13324 Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension
A Phase 3 study, sponsored by Aerie Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 411
- Enrollment target
NCT02207491 is a Phase 3 study that has completed, run by Aerie Pharmaceuticals. The registered enrollment target is 411 participants.
The verdict
NCT02207491, a Phase 3 study, has completed, sponsored by Aerie Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 411 participants
- Enrollment target
Study Summary
To evaluate the ocular hypotensive efficacy and ocular and systemic safety of AR-13324 Ophthalmic Solution, 0.02% compared to the active comparator Timolol maleate Ophthalmic Solution, 0.5%
Interventions
- OTHER Placebo
- DRUG AR-13324 Ophthalmic Solution 0.02%
- DRUG Timolol maleate Ophthalmic Solution 0.5% BID
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 411 participants |
| Start Date | 2014-07 |
| Est. Completion | 2015-03 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02207491
The ClinicalTrials.gov registry entry for NCT02207491 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 411 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Aerie Pharmaceuticals, which has 32 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT02207491 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02207491 about?
NCT02207491 is a clinical study titled "Double-masked Study of AR-13324 Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension". To evaluate the ocular hypotensive efficacy and ocular and systemic safety of AR-13324 Ophthalmic Solution, 0.02% compared to the active comparator Timolol maleate Ophthalmic Solution, 0.5%
What is the current status of trial NCT02207491?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 411 participants. The study started on 2014-07. Estimated completion is 2015-03.
What interventions are being tested in trial NCT02207491?
The interventions under investigation include: Placebo (OTHER), AR-13324 Ophthalmic Solution 0.02% (DRUG), Timolol maleate Ophthalmic Solution 0.5% BID (DRUG).
Who is sponsoring clinical trial NCT02207491?
This trial is sponsored by Aerie Pharmaceuticals, which has 32 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.